Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen clinical programs — 31 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Status
Public
HQ
225 Binney Street, Cambridge, MA 02142, US
Employees
7,534
Programs
31
Drugs
45
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Biogen projects

31 ClinicalTrials.gov programs sponsored by Biogen.

Biogen has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

31 programs

Clinical programs

  1. 105MS306

    Biogen

    Relapsing Remitting Multiple Sclerosis (RRMS)

    phase 3 small molecule active

    1 trial

  2. 230LE301

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. 230LE303

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  4. 230LE304

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  5. 230LE306

    Biogen

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  6. 233AS303

    Biogen

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  7. 299AR301

    Biogen

    Kidney Transplant Recipients with Late Antibody-Mediated Rejection

    phase 3 small molecule active

    1 trial

  8. 299IG301

    Biogen

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  9. BG00012

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  10. BIIB019 (Daclizumab)

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  11. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  12. BIIB111

    Biogen

    Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

    phase 3 small molecule active

    1 trial

  13. Bardoxolone methyl

    Biogen

    Pulmonary Hypertension

    phase 3 small molecule terminated

    1 trial

  14. Felzartamab

    Biogen

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  15. Hard capsules, BIIB141

    Biogen

    Friedreich’s ataxia

    phase 3 small molecule active

    1 trial

  16. Placebo

    Biogen

    Multiple Sclerosis, Remittent Progressive

    phase 3 small molecule completed

    1 trial

  17. SPINRAZA 28 mg, SPINRAZA 50 mg

    Biogen

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  18. SPINRAZA 50 mg, SPINRAZA 28 mg

    Biogen

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  19. TECFIDERA

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. Tofersen

    Biogen

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  21. dimethyl fumarate

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  22. 283PD201

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  23. 299AR201

    Biogen

    Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

    phase 2 small molecule active

    1 trial

  24. EnEPC-CLI-01

    Biogen

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  25. Felzartamab

    Biogen

    Immunoglobulin A (IgA) Nephropathy

    phase 2 small molecule completed

    1 trial

  26. 277HV101

    Biogen

    Spinal muscular atrophy

    phase 1 small molecule active

    1 trial

  27. BIIB115

    Biogen

    Healthy Volunteer

    phase 1 small molecule active

    1 trial

  28. Placebo oral capsule

    Biogen

    Healthy

    phase 1 small molecule completed

    1 trial

  29. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    phase 1 small molecule active

    1 trial

  30. Dimethyl fumarate

    Biogen

    Multiple Sclerosis

    approved small molecule completed

    1 trial

  31. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Biogen have?

31 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.